| ACOSOG | American College of Surgeons Oncology Group | |
| ABC | advanced breast cancer | |
| ABC5 | 5th ESO-ESMO international consensus guidelines for advanced breast cancer | 第5回ESO-ESMO進行乳癌に対する国際コンセンサスガイドライン |
| AI | aromatase inhibitor | アロマターゼ阻害薬 |
| ALND | axillary lymph node dissection | 腋窩リンパ節郭清 |
| AOR | annual odds of recurrence | 年間再発率 |
| APBI | accelerated partial breast irradiation | 加速乳房部分照射 |
| ART | assisted reproductive technology | 生殖補助医療 |
| ASCO | American Society of Clinical Oncology | 米国臨床腫瘍学会 |
| ASTRO | American Society for Radiation Oncology | 米国放射線腫瘍学会 |
| BIA-ALCL | breast implant-associated anaplastic large cell lymphoma | ブレスト・インプラント関連未分化大細胞型リンパ腫 |
| BMA | bone modifying agents | 骨修飾薬 |
| BMD | bone mineral density | 骨密度 |
| BOOP | bronchiolitis obliterans organizing pneumonia | |
| CALGB | Cancer and Leukemia Group B | |
| CAM | complementary and alternative medicine | 補完・代替療法 |
| CBR | clinical benefit rate | リニカルベネフィット率 |
| CF | conventional fractionation | 通常分割 |
| CGA | comprehensive geriatric assesment | 高齢者機能的総合評価 |
| CI | confidence interval | 信頼区間 |
| CR | complete response | 完全奏効 |
| CTV | clinical target volume | 臨床標的体積 |
| DBCG | Danish Breast Cancer Cooperative Group | |
| DCIS | ductal carcinoma in situ | 非浸潤性乳管癌 |
| DDFS | distant disease-free survival | |
| DFI | disease-free interval | |
| DFS | disease-free survival | 無病生存期間，無病生存率 |
| DIEP flap | deep inferior epigastric perforator flap | 深下腹壁動脈穿通枝皮弁 |
| DRFS | distant relapse-free survival | |
| EBC | early breast cancer | 早期乳癌 |
| EBCTCG | Early Breast Cancer Trialists’ Collaborative Group | |
| ECOG | Eastern Cooperative Oncology Group | |
| EFS | event-free survival | 無イベント生存率 |
| EIC | extensive intraductal component | 広範な乳管内進展 |
| EORTC | European Organisation for Research and Treatment of Cancer | |
| EORTC QLQ | European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire | |
| ER | estrogen receptor | エストロゲン受容体 |
| ERE | estrogen responsive element | エストロゲン応答配列 |
| ESMO | European Society for Medical Oncology | 欧州臨床腫瘍学会 |
| FACT | Functional Assessment of Cancer Therapy | |
| FDA | Food and Drug Administration | 米国食品医薬品局 |
| FN | febrile neutropenia | 発熱性好中球減少症 |
| FSH | follicle stimulating hormone | 卵胞（濾胞）刺激ホルモン |
| gBRCA | germline BRCA | 生殖細胞系列BRCA |
| G-CSF | granulocyte-colony stimulating factor | 顆粒球コロニー刺激因子 |
| GPA | graded prognostic assessment | |
| GTV | gross tumor volume | 肉眼的腫瘍体積 |
| HBV | hepatitis B virus | B型肝炎ウイルス |
| HER2 | human epidermal growth factor receptor type 2 | ヒト上皮増殖因子受容体2型 |
| HF | hypofractionation | 寡分割 |
| HR | hazard ratio | ハザード比 |
| HR | hormone receptor | ホルモン受容体 |
| HRD | homologous recombination deficiency | 相同組み換え修復不全 |
| HRT | hormone replacement therapy | ホルモン補充療法 |
| IBCSG | International Breast Cancer Study Group | |
| IBTR | ipsilateral breast tumor recurrence | 温存乳房内再発 |
| IDFS | invasive disease-free survival | 浸潤癌の無病生存期間 |
| IHC | immunohistochemical staining | 免疫組織化学的方法 |
| IMRT | intensity modulated radiation therapy | 強度変調放射線治療 |
| ITT | intention to treat | |
| JCOG | Japan Clinical Oncology Group | 日本臨床腫瘍研究グループ |
| LABC | locally advanced breast cancer | 局所進行乳癌 |
| LCIS | lobular carcinoma in situ | 非浸潤性小葉癌 |
| LH | luteinizing hormone | 黄体形成ホルモン |
| LH-RH | luteinizing hormone-releasing hormone | 黄体形成ホルモン放出ホルモン |
| LVEF | left ventricular ejection fraction | 左室駆出率 |
| MBC | metastatic breast cancer | 転移・再発乳癌 |
| MMR | mismatch repair | ミスマッチ修復機能 |
| MSI | microsatellite instability | マイクロサテライト不安定性 |
| NAC | neoadjuvant chemotherapy | 術前化学療法 |
| NCCN | National Comprehensive Cancer Network | 全米総合がん情報ネットワーク |
| NCI | National Cancer Institute | 米国国立癌研究所 |
| NGS | next generation sequencing | 次世代シークエンス |
| NSABP | National Surgical Adjuvant Breast and Bowel Project | |
| NSAI | non-steroidal aromatase inhibitor | 非ステロイド性アロマターゼ阻害薬 |
| NSAIDs | non-steroidal anti-inflammatory drugs | 非ステロイド消炎鎮痛薬 |
| NSM | nipple-sparing mastectomy | 乳頭温存乳房全切除術 |
| ONJ | osteonecrosis of the jaw | 顎骨壊死 |
| OPBCS | oncoplastic breast-conserving surgery | 乳房温存オンコプラスティックサージャリー |
| OPBS | oncoplastic breast surgery | 乳房オンコプラスティックサージャリー |
| OR | odds ratio | オッズ比 |
| ORR | overall response rate | 全奏効割合，全奏効率 |
| OS | overall survival | 全生存期間，全生存率 |
| PARP | poly（ADP-ribose）polymerase | ポリADPリボースポリメラーゼ |
| pCR | pathological complete response | 病理学的完全奏効 |
| PD | progressive disease | 進行 |
| PD-1 | programmed cell death-1 | |
| PD-L1 | programmed cell death 1 ligand 1 | |
| PFS | progression free survival | 無増悪生存期間，無増悪生存率 |
| PgR | progesterone receptor | プロゲステロン受容体 |
| PMRT | postmastectomy radiation therapy | 乳房全切除術後放射線療法 |
| PS | performance status | パフォーマンスステータス |
| PTV | planning target volume | 計画標的体積 |
| QALYs | quality-adjusted life-years | |
| QOL | quality of life | 生活の質 |
| RANKL | receptor activator of nuclear factor κ-B ligand | |
| RCT | randomized controlled trial | ランダム化比較試験 |
| RDI | relative dose intensity | |
| RFA | radiofrequency ablation | ラジオ波熱凝固療法 |
| RFS | relapse-free survival，recurrence-free survival | 無再発生存期間，無再発生存率 |
| RI | radioisotope | ラジオアイソトープ |
| RR | risk ratio | リスク比 |
| RS | recurrence score | |
| RTOG | Radiation Therapy Oncology Group | 米国腫瘍放射線治療グループ |
| RT-PCR | reverse transcription polymerase chain reaction | |
| SABCS | San Antonio Breast Cancer Symposium | |
| SE | standard error | 標準誤差 |
| SEER | Surveillance, Epidemiology, and End Results | |
| SERD | selective estrogen receptor degrader | 選択的エストロゲン受容体分解薬 |
| SERM | selective estrogen receptor modulator | 選択的エストロゲン受容体モジュレーター |
| SLE | systemic lupus erythematosus | 全身性エリテマトーデス |
| SLN | sentinel lymph node | センチネルリンパ節 |
| SLNB | sentinel lymph node biopsy | センチネルリンパ節生検 |
| SRE | skeletal-related event | 骨関連事象 |
| SRS | stereotactic radiosurgery | 定位手術的照射 |
| SRT | stereotactic radiotherapy | 定位［的］放射線治療 |
| SSM | skin-sparing mastectomy | 皮膚温存乳房全切除術 |
| SSO | Society of Surgical Oncology | |
| SSRI | selective serotonin reuptake inhibitor | 選択的セロトニン再取込み阻害薬 |
| STI | stereotactic irradiation | 定位放射線照射 |
| SWOG | Southwest Oncology Group | |
| TE | tissue expander | 組織拡張器 |
| TMB-H | tumor mutational burden-high | 腫瘍遺伝子変異量高スコア |
| TNBC | triple negative breast cancer | トリプルネガティブ乳癌 |
| TPC | treatment of physician’s choice | |
| TRK | tropomyosin receptor kinase | 受容体チロシンキナーゼ |
| TTNT | time to next treatment | 次治療までの期間 |
| TTP | time to progression | 無増悪期間，病勢進行までの期間 |
| VEGF | vascular endothelial growth factor | 血管内皮増殖因子 |
| WHO | World Health Organization | 世界保健機関 |
| YAM | young adult mean | 若年成人平均値 |